AstraZeneca returns several compounds to Targacept

Mon Feb 10, 2014 5:01pm EST

Feb 10 (Reuters) - Biotech company Targacept Inc said British drugmaker AstraZeneca would return rights to several pre-clinical compounds, sending the U.S. company's shares down 10 percent in extended trading.

A licensing agreement, signed in 2005, continues for the remaining compounds, including AZD1446, a potential treatment for Alzheimer's disease.

The amendment to the agreement becomes effective 90 days after Feb. 7, Targacept said in a filing with the U.S. Securities and Exchange Commission. ()

Targacept shares closed at $4.96 on the Nasdaq on Monday.

A couple walks along the rough surf during sunset at Oahu's North Shore, December 26, 2013. REUTERS/Kevin Lamarque

Find your dream retirement town

Florida? Hawaii? Reuters has teamed up with Zillow to give you the power to customize a list of your best places to retire.  Video | Full Article